pancreatic ductal adenocarcinoma
GPTKB entity
Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:age |
65 to 80 years
|
| gptkbp:body_style |
ductal cells
|
| gptkbp:can_metastasize_to |
liver
lungs peritoneum |
| gptkbp:caused_by |
weight loss
abdominal pain jaundice |
| gptkbp:clinical_trial |
Phase IV
Phase II Phase III ongoing research Phase I rapid progression poor response to treatment high rate of recurrence |
| gptkbp:current_use |
gptkb:Company
gallstones chronic pancreatitis |
| gptkbp:end_of_life |
varies by stage
|
| gptkbp:genetic_diversity |
gptkb:KRAS
T P53 CDK N2 A SMA D4 |
| https://www.w3.org/2000/01/rdf-schema#label |
pancreatic ductal adenocarcinoma
|
| gptkbp:lifespan |
10% to 20%
|
| gptkbp:number_of_stages |
stage I
stage IV stage II stage III |
| gptkbp:occurs_in |
high in developed countries
|
| gptkbp:origin |
pancreas
|
| gptkbp:research_focus |
biomarkers
early detection new therapies |
| gptkbp:risk_factor |
gptkb:Company
obesity family history smoking |
| gptkbp:screenings |
no standard screening
|
| gptkbp:social_responsibility |
gptkb:MRI
CT scan poor endoscopic ultrasound increasing incidence invasive carcinoma higher in men desmoplastic stroma ductal differentiation higher in African Americans |
| gptkbp:symptoms |
nausea
vomiting |
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine radiation therapy chemotherapy targeted therapy late diagnosis high treatment resistance limited treatment options |
| gptkbp:bfsParent |
gptkb:ductal_adenocarcinoma
|
| gptkbp:bfsLayer |
4
|